Tirofiban-d9

更新时间：2024-04-05 21:26:16

Tirofiban-d9结构式	常用名	Tirofiban-d9	英文名	Tirofiban-d9
	CAS号	1332075-40-7	分子量	449.65
	密度	N/A	沸点	N/A
	分子式	C₂₂H₂₇D₉N₂O₅S	熔点	N/A
	MSDS	N/A	闪点	N/A

Tirofiban-d9用途

替罗非班-d9是氘标记的替罗非班。

英文名	Tirofiban-d9

描述	替罗非班-d9是氘标记的替罗非班。
相关类别	研究领域 >> 心血管疾病信号通路 >> 细胞骨架 >> Integrin
体外研究	氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注[1]。
参考文献	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46. [3]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100. [4]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49. [5]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19. [6]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53.

分子式	C₂₂H₂₇D₉N₂O₅S
分子量	449.65